Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
Fast, flexible space allows clinical trials to start when needed. A trial can become operational, pivot or scale without traditional capital building expenditures
Subscribe To Our Newsletter & Stay Updated
